Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation

NCT05321498 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped MCI patients will now be enrolled in the XPro1595-AD-02 study.

Conditions

Mild Cognitive Impairment (MCI)
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Mental Disorders

Interventions

DRUG: XPro1595
DRUG: Placebo

Sponsor

Inmune Bio, Inc.